A compound of Formula I, enantiomers, diasteriomers, tautomers orpharmaceutically acceptable salts thereof,wherein R1, R2, R3, R4 and R5 are defined herein, are useful as JAK kinaseinhibitors. A pharmaceutical composition that includesa compound of Formula I and a pharmaceutically acceptable carrier, adjuvant orvehicle, and methods of treating or lessening theseverity of a disease or condition responsive to the inhibition of JAK kinaseactivity in a patient are disclosed.
